CP216

About Consegna Pharma

Consegna Pharma is a private, pre-revenue biotech developing long-acting injectable formulations of off-patent drugs using its Computational Drug Delivery™ platform. Its lead program, CP216, is a long-acting naloxone designed to prevent renarcotization in opioid overdose reversal, addressing a critical limitation of current short-acting antidotes. The company utilizes the FDA's 505(b)(2) regulatory pathway to potentially accelerate development and reduce risk. Its business model appears focused on out-licensing its formulated product portfolio to larger pharmaceutical partners for commercialization.

Therapeutic Areas